Guardant Health, Inc., a leading precision oncology company, and Meaningful Insights Biotech Analytics (MiBA), an innovative healthcare technology company, announced a unique partnership aimed at optimizing the use of biomarker testing and data analytics to advance precision medicine in patient care throughout the MiBA Network.
Recognizing the evolving landscape of precision medicine, the collaboration combines MiBA’s cutting-edge artificial intelligence (AI) technologies and high-quality oncology data with Guardant’s expertise in comprehensive tumor profiling and circulating tumor DNA (ctDNA) monitoring. Together, the companies aim to transform cancer care by driving personalized, data-driven approaches that facilitate broad, consistent access to innovative treatments that can enhance patient outcomes.
Also Read: Epitopea and Genevant Partner in New Collaboration
“Precision oncology is redefining cancer treatment, enabling more tailored treatment through the use of biomarkers and monitoring of circulating tumor DNA,” said Steven Collora, senior vice president, key accounts and strategic initiatives, at Guardant Health. “Our partnership with MiBA allows us to deliver a multidimensional view of what is driving cancer, using real-world data, to empower healthcare providers and patients to take a more personalized approach to cancer care.”
Mark Moch, MiBA Managing Partner, stated, “This collaboration with Guardant Health is an innovative approach to precision oncology. By leveraging our technology and data insights, we can enhance understanding and accessibility of genomic testing, ensuring that every patient receives the precise care recommended in clinical guidelines.”
The initiative will equip stakeholders across the healthcare continuum with vital knowledge about and access to biomarker testing and cancer recurrence and response monitoring tools, along with data insights along the continuum of care, ultimately improving standards of care for patients with cancer.
Source: Businesswire